Study Overview
This study focused on the effectiveness and safety of Cinnatropin®, a biosimilar growth hormone, in treating growth-related disorders in children and adolescents.
Key Findings
- A total of 20,465 patients participated, with 405 in a detailed analysis.
- The most common issue was growth hormone deficiency.
- After 12 months, the average height standard deviation score (HSDS) improved significantly:
- From -1.71 to -1.32 in the general group.
- From -1.84 to -1.49 in the detailed analysis group.
- Over 80% of younger patients achieved their height growth goals within a year.
Safety Profile
The majority of side effects were mild, including:
- Injection site reactions
- Headaches
Most adverse events were not serious.
Conclusions
Cinnatropin® is effective in improving height over one year and has an acceptable safety profile.
Opportunities for Clinics and Patients
Based on the trial data, clinics can:
- Set clear goals for treatment outcomes.
- Use AI tools tailored to enhance patient management.
- Start with pilot projects to track results and improve care.
Contact Us for AI Solutions
If you’re interested in AI solutions for medical management, reach out to us:
